Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
前收盤價
US$20.73
−US$0.31 · -1.47%
盤中時間採用ET。市場資料可能有所延遲。
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
日內區間
目前US$20.73
52週區間
目前US$20.73
盤中時間採用ET。市場資料可能有所延遲。
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
日內區間
目前US$20.73
52週區間
目前US$20.73
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 6348.9萬 USD | 4136.4萬 USD | 3696.6萬 USD | 2565.4萬 USD | 1097.7萬 USD |
| 銷售、一般及管理費用 | 2054.7萬 USD | 1665.1萬 USD | 768.2萬 USD | 717.6萬 USD | 463.3萬 USD |
| 營業費用 | 8403.6萬 USD | 5801.5萬 USD | 4464.8萬 USD | 3283萬 USD | 1561萬 USD |
| 利息收入 | 1129.7萬 USD | 426.1萬 USD | 58.1萬 USD | 14.9萬 USD | — |
| 利息支出 | 6.3萬 USD | 10.7萬 USD | 15.2萬 USD | 14.4萬 USD | 22.4萬 USD |
| 折舊和攤銷 | 137.5萬 USD | 164.5萬 USD | 147.8萬 USD | 100.6萬 USD | 36.4萬 USD |
| 營業利益 | −8403.6萬 USD | −5801.5萬 USD | −4464.8萬 USD | −3283萬 USD | −1561萬 USD |
| 淨利 | −7415.1萬 USD | −5798.2萬 USD | −4282.3萬 USD | −3218萬 USD | −892.7萬 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$62.33
上漲空間 200.68%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年6月21日 | 1:12 | — | — |
已生效 2024年6月21日
1:12
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM602萬0.01%715.37億 USD0.19%US$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI568.02萬0.00%6893億 USD0.03%US$340.02-3.52%
Vanguard Extended Market ETFVXF268.07萬0.00%302億 USD0.05%US$211.44-3.21%
iShares Russell 2000 Value ETFIWN172.09萬0.01%130.46億 USD0.24%US$198.84-2.08%
iShares Biotechnology ETFIBB151.46萬0.01%105.27億 USD0.44%US$199.54-2.05%
Vanguard Russell 2000 ETFVTWO126.59萬0.01%168億 USD0.06%US$103.76-2.76%
Vanguard U.S. Momentum Factor ETFVFMO89.5萬0.05%19億 USD0.13%US$193.88-3.13%
iShares Micro-Cap ETFIWC68.16萬0.06%10.88億 USD0.60%US$157.87-3.19%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Value ETFIWN
iShares Biotechnology ETFIBB
Vanguard Russell 2000 ETFVTWO
Vanguard U.S. Momentum Factor ETFVFMO
iShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。